ALPHARETTA, Ga., March 17, 2016 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV), announced today the receipt of U.S. Patent Number 9,161,768 from the U.S. Patent and Trademark Office, entitled “Extracorporeal Pressure Shock Wave Devices with Reversed Applicators and Methods for Using These Devices”. The patent life extends to August 2030.
The patent includes twelve claims relating to the special construction of the reversed applicators. These new reversed applicators have their aperture along the large axis of the reflector, which is completely different from the classic construction of pressure shock wave applicators that have their aperture along their small axis of the reflector. This construction gives the advantage to treat a larger area in one position of the applicator, based on the fact that the targeted area is intersecting the applicator’s focal volume on its longitudinal plane. This is opposite of classic design and construction of pressure shock wave applicators which instead uses the transversal plane. Furthermore, these new applicators are capable of sending into the targeted tissue both focused pressure shock waves and radial pressure waves that are emerging at the point of origin of acoustic pressure shock waves. These hybrid shock waves, when combined with larger treatment area, give a significant increase in their overall efficiency.
The claims are also covering methods to use these reversed applicators for treating heart, pericardium or a portion of the pericardial cavity, for breaking fibrotic tissue, for repairing hypertrophic lesions or organ adhesions or capsular contracture or damaged tissue, for treating aseptic or bacterial or viral or fungal infections or prostatitis, for stimulation, proliferation and differentiation of stem cells, for gene therapy, for regeneration or stimulation or repair of nerve cells and for treating bone spurs and heterotopic ossifications.
“The design originality for these reversed applicators, which is a complete departure from the classic design approach for pressure shock wave applicators, combined with the broad spectrum of applications where the reversed applicators can be used, makes this new patent very important to us. Through these new applicator designs we can extend the reach of our technology in many new medical fields and increase efficiency of our treatments, which fits with our long term strategy to maximize the value of our pressure shock wave technology,” commented Kevin A. Richardson, II, Chairman of the board of directors of SANUWAVE.
SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 52 patents (issued or pending) in the field of shock waves used in medical and non-medical applications.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Source:SANUWAVE Health, Inc.